The U.S. Food and Drug Administration has granted the designation for the company’s personalized cancer therapy, EVX-01, in combination with KEYTRUDA.
In December 2022, Evaxion received FDA approval to proceed with its Phase 2b clinical trial, where EVX-01 is given in combination with KEYTRUDA to patients with metastatic melanoma. On January 17, 2023, Evaxion furthermore received fast track designation for the vaccine candidate. The fast track is designed to expedite the FDA’s review of innovative, new drugs that demonstrate the potential to address an unmet medical need.
”We are extremely pleased that our cancer vaccine candidate EVX-01 has received the FDA fast track designation, as it enables a potentially faster approval of the vaccine. This is first and foremost to the benefit of the patients. And it is a great validation of our AI platform, PIONEER, and our drug development candidate,” says Per Norlén, CEO at Evaxion.
A peptide-based cancer immunotherapy
EVX-01 is a peptide-based cancer immunotherapy and is Evaxion’s most advanced clinical asset. Under the program, a drug is generated for each patient based on gene analysis of their tumors and on matching with their immune system. This process is made possible by the company’s AI platform, PIONEER.
The ongoing Phase 2b study is conducted at clinical sites across the United States, Europe, and Australia. It is carried out in collaboration with Merck, supplying its PD-1 inhibitor KEYTRUDA. The trial was initiated in Australia with the enrollment of the first patient in September 2022.
Photo of Per Norlén: Jenny Leyman